Bluejay Diagnostics EBIT

The latest EBIT for BJDX is $1.5M as of June 2026. That compares with $-6.9M in the prior-year period — up 122.0% year over year. That is below the sector sector average of $2.6T. Investors often review this figure alongside Bluejay Diagnostics's historical trend and sector peers before judging valuation or financial health.

Over the past year, BJDX's EBIT moved from $-6.9M to $1.5M — a 122.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Bluejay Diagnostics's operating scale or balance-sheet position.

Against its sector companies, BJDX currently prints $1.5M for EBIT, while the sector average sits near $2.6T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Bluejay Diagnostics's growth, margins, and balance sheet.

A EBIT figure of $1.5M for BJDX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.6T. Explore the charts below for those layers of context.

After noting BJDX's EBIT ($1.5M), review year-over-year change from $-6.9M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.